HIV/AIDS Epidemiology and Prevention: Dr. Chatté is deeply engaged in research aimed at understanding the epidemiology of HIV/AIDS, identifying risk factors for transmission, and developing effective prevention strategies. He is particularly interested in innovative approaches to HIV prevention, including vaccine development and pre-exposure prophylaxis (PrEP).
Molecular Diagnostics of Infectious Diseases: With expertise in molecular biology techniques, Dr. Chatté explores the use of advanced diagnostic methods for the detection and characterization of infectious agents such as HIV, hepatitis C virus (HCV), and other pathogens. He is involved in developing and validating molecular assays for accurate and timely diagnosis of infectious diseases.
Antimicrobial Resistance Monitoring: Dr. Chatté’s research addresses the growing threat of antimicrobial resistance by investigating mechanisms of resistance development and spread among bacterial pathogens. He conducts surveillance studies to monitor antimicrobial resistance patterns and assess the impact of interventions on controlling resistance.
Vaccine Development and Immunology: Dr. Chatté is passionate about vaccine research, particularly the development of novel vaccine candidates against infectious diseases such as HIV. He explores innovative vaccine platforms and adjuvant strategies to enhance immune responses and induce long-lasting protection against pathogens.
Health Systems Strengthening: Recognizing the importance of robust health systems in disease control and prevention, Dr. Chatté conducts research on health system strengthening interventions. His work aims to identify barriers and facilitators to effective healthcare delivery, improve access to essential services, and enhance the resilience of health systems, especially in resource-limited settings.
Global Health Equity and Access to Care: Dr. Chatté’s research agenda includes a focus on promoting health equity and ensuring equitable access to healthcare services for underserved populations. He investigates disparities in healthcare access, barriers to care-seeking behavior, and interventions to address health inequalities.
Publication Top Noted:
Title: High prevalence of cervical high-risk human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N’Djamena, Chad
- Authors: Bouassa, R.-S.M., Nodjikouambaye, Z.A., Sadjoli, D., Koyalta, D., Belec, L.
- Journal: PLoS ONE
- Year: 2019
- Volume: 14
- Issue: 6
- Page: e0217486
Title: Low prevalence of common sexually transmitted infections contrasting with high prevalence of mycoplasma asymptomatic genital carriage: A community-based cross-sectional survey in adult women living in N’Djamena, Chad
- Authors: Compain, F., Nodjikouambaye, Z.A., Sadjoli, D., Podglajen, I., Bélec, L.
- Journal: Open Microbiology Journal
- Year: 2019
- Volume: 13
- Issue: 1
- Pages: 222–229
Title: Accuracy of curable sexually transmitted infections and genital mycoplasmas screening by multiplex real-time PCR using a self-collected veil among adult women in Sub-Saharan Africa
- Authors: Nodjikouambaye, Z.A., Compain, F., Sadjoli, D., Koyalta, D., Belec, L.
- Journal: Infectious Diseases in Obstetrics and Gynecology
- Year: 2019
- Volume: 2019
- Pages: 8639510
Title: Usefulness of simultaneous screening for HIV and hepatitis C-specific antibodies and hepatitis B surface antigen by capillary-based multiplex immunochromatographic rapid test to strengthen prevention strategies and linkage to care in childbearing-aged women living in resource-limited settings
- Authors: Bouassa, R.-S.M., Nodjikouambaye, Z.A., Sadjoli, D., Koyalta, D., Bélec, L.
- Journal: Open Forum Infectious Diseases
- Year: 2018
- Volume: 5
- Issue: 5
Title: Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N’Djamena, Chad: Findings from a cross-sectional study
- Authors: Adawaye, C., Fokam, J., Kamangu, E., Vaira, D., Moutschen, M.
- Journal: BMC Research Notes
- Year: 2017
- Volume: 10
- Issue: 1
- Page: 589